产品
编 号：F752585
产品类型
规格
价格
是否有货
结构图
CAS No: 2419087-89-9
产品详情
生物活性：
Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies.
体内研究：
Mazorelvimab (0.03-1.0 mg/kg；肌肉注射；单剂量) 以剂量依赖性方式提高了被狂犬病毒 (RABV) 感染的仓鼠的存活率。Mazorelvimab (0.003-1mg/kg；肌肉注射；单剂量) 以剂量依赖性方式提高 RABV 感染的仓鼠的存活率。Mazorelvimab (0.003-0.03 mg/kg) 对未感染病毒的叙利亚仓鼠血清 RVNA 水平无显著干扰。Mazorelvimab (0.03-1 mg/kg；肌肉注射；单剂量) 对感染 RABV (BD06) 的比格犬具有保护作用。Animal Model:RABV infected Syrian hamster.
Dosage:0.03, 0.1, 0.3 and 1.0 mg/kg.
Administration:Right gastrocnemius muscle injection; single dose.
Result:Improved the survival rate.
Animal Model:10 two-month-old female Syrian hamsters/six-month-old beagles infected with RABV (BD06).
Dosage:0.003, 0.01, 0.03, 0.1, 0.3 and 1 mg/kg.
Administration:Right gastrocnemius muscle or masseter muscle injection; single dose.
Result:Improved survival rate and had protective effect.
体外研究：
Mazorelvimab (0.01-100 μg/mL) 以剂量依赖性方式对 CVS-11 感染的 BSR 细胞显示出细胞毒性，但对未感染的 BSR 细胞无影响。
Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies.
体内研究：
Mazorelvimab (0.03-1.0 mg/kg；肌肉注射；单剂量) 以剂量依赖性方式提高了被狂犬病毒 (RABV) 感染的仓鼠的存活率。Mazorelvimab (0.003-1mg/kg；肌肉注射；单剂量) 以剂量依赖性方式提高 RABV 感染的仓鼠的存活率。Mazorelvimab (0.003-0.03 mg/kg) 对未感染病毒的叙利亚仓鼠血清 RVNA 水平无显著干扰。Mazorelvimab (0.03-1 mg/kg；肌肉注射；单剂量) 对感染 RABV (BD06) 的比格犬具有保护作用。Animal Model:RABV infected Syrian hamster.
Dosage:0.03, 0.1, 0.3 and 1.0 mg/kg.
Administration:Right gastrocnemius muscle injection; single dose.
Result:Improved the survival rate.
Animal Model:10 two-month-old female Syrian hamsters/six-month-old beagles infected with RABV (BD06).
Dosage:0.003, 0.01, 0.03, 0.1, 0.3 and 1 mg/kg.
Administration:Right gastrocnemius muscle or masseter muscle injection; single dose.
Result:Improved survival rate and had protective effect.
体外研究：
Mazorelvimab (0.01-100 μg/mL) 以剂量依赖性方式对 CVS-11 感染的 BSR 细胞显示出细胞毒性，但对未感染的 BSR 细胞无影响。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备